TABLE 2.
Anti-proliferative activity for compounds 3b, 3d, 4d, and 9b against human leukemia-lymphoma-derived cell lines and solid tumor-derived cell-lines.
| Compounds | CC50 (µM) a | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| CCRF-CEM b | WIL-2NS c | CCRF-SB d | SK-MEL28 e | SK-MES1 f | DU145 g | HeLa h | CRL 7065 i | |||
| 3b | 0.5 ± 0.1 | >100 | 0.35 ± 0.07 | 6.2 ± 1.3 | 6.8 ± 3.5 | 5.1 ± 0 | 7.1 ± 2.7 | 0.75 ± 0.05 | ||
| 3d | 0.07 ±0.02 | >100 | 7.9 ± 0.9 | >100 | >100 | >100 | >100 | 0.37 ± 0.04 | ||
| 4d | 3.3 ±1.7 | 64 ± 10 | 0.51 ± 0.13 | >100 | >100 | >100 | >100 | 1.7 ± 0.1 | ||
| 9b | 5.5 ±1.8 | 23 ± 7 | 8.5 ± 3.2 | 2.6±0.7 | 9.9±3.1 | 5.2 ± 0.4 | 5.4 ± 0.7 | 6.7 ± 2.4 | ||
| Vincristine | 0.003 ± 0.001 | 0.006 ± 0.002 | 0.003 ± 0.001 | >4 | 0.01±0.02 | 0.02 ± 0.01 | 0.05 ± 0.02 | >4 | ||
| Doxorubicin | 0.02±0.01 | 0.06±0.01 | 0.03±0.02 | 1.1±0.2 | 0.65±0.05 | 0.3 ± 0.1 | 1.8 ± 0.2 | 2.0 ± 0.2 | ||
Control is represented by CRL 7065 cell line. Vincristine and Doxorubicin were used as positive controls.
Compound concentration required to reduce cell proliferation by 50%, as determined by the MTT method, under conditions allowing untreated controls to undergo at least three consecutive rounds of multiplication. Data represent mean values (±SD) for three independent determinations.
CD4+ human acute T-lymphoblastic leukemia.
Human splenic B-lymphoblastoid cells.
Human acute B-lymphoblastic.
Human skin melanoma.
Human lung squamous carcinoma.
Human prostate carcinoma.
Human cervix carcinoma.
Human foreskin fibroblasts.